Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Impact of NOL Index Intraoperative Guided Remifentanil Analgesia

NCT: NCT04402242 · TERMINATED

NCT IDNCT04402242
StatusTERMINATED
Start Date2021-04-13
Completion2023-07-10
SponsorHopital Foch (OTHER)
First posted
Last updated

Brief Summary

The Physiological Monitoring Device (PMD-200™) system is comprised of a monitor and a designated finger probe containing 4 sensors. The sensors included are Photoplethysmography (PPG), Galvanic Skin Response (GSR), Accelerometer for movement (ACC) and Thermistor for peripheral temperature (TMP). The PMD-200 is intended to be used for assessing the nociception level in anesthetized patients. The purpose of the study is confirmation of a reduction in the dosage of remifentanil allowed by the monitoring of nociception by the NOL which could open the way to a double control of the administration of anesthetic agents: control of the administration of hypnotics by the bispectral index (BIS) and control of the administration of opiate by the NOL.

Frequently Asked Questions

What is Impact of NOL Index Intraoperative Guided Remifentanil Analgesia?

Impact of NOL Index Intraoperative Guided Remifentanil Analgesia is a clinical trial registered under NCT04402242. Current status: TERMINATED.

What is the status of NCT04402242?

The current status of NCT04402242 (Impact of NOL Index Intraoperative Guided Remifentanil Analgesia) is: TERMINATED.

When did Impact of NOL Index Intraoperative Guided Remifentanil Analgesia start?

Impact of NOL Index Intraoperative Guided Remifentanil Analgesia started on 2021-04-13.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.